PDS Biotechnology to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
FLORHAM PARK, N.J., Sept. 13, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s proprietary Versamune® T-cell activating technology, announced today that its management will present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit.
The presentation will provide an update on the three ongoing PDS0101 Phase 2 clinical trials. The talk will also provide updates on progression of two other investigational pipeline products PDS0102 (Versamune®-TARP) and PDS0103 (Versamune®-MUC1) into human clinical trials. The conference is taking place virtually from September 21 - 23, 2021. Details for the presentation are as follows:
Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit:
Following the conference a webcast replay of the presentation will be available on the Investor section of the company’s website, https://pdsbiotech.com/.
About PDS Biotechnology
Media & Investor Relations Contact:
Face the Music: The New Age of Bluetooth
Brunch Served in ITEXPO #TECHSUPERSHOW Expo Hall
WiFi6: Securing the Remote Future